相似文献
1
Editorial: Neuroprotection and disease modification in Parkinson's disease: Volume II.
Front Pharmacol. 2023 Jan 9;13:1121513. doi: 10.3389/fphar.2022.1121513. eCollection 2022.
2
Editorial: Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease.
Front Aging Neurosci. 2023 Jul 14;15:1247256. doi: 10.3389/fnagi.2023.1247256. eCollection 2023.
3
Editorial: Neuroprotection and Disease Modification in Parkinson's Disease.
Front Pharmacol. 2021 Dec 8;12:813471. doi: 10.3389/fphar.2021.813471. eCollection 2021.
4
New hopes for disease modification in Parkinson's Disease.
Neuropharmacology. 2020 Jul;171:108085. doi: 10.1016/j.neuropharm.2020.108085. Epub 2020 Apr 13.
5
GardeninA confers neuroprotection against environmental toxin in a Drosophila model of Parkinson's disease.
Commun Biol. 2021 Feb 5;4(1):162. doi: 10.1038/s42003-021-01685-2.
6
Disease modification in Parkinson's disease.
Drugs Aging. 2011 Aug 1;28(8):605-15. doi: 10.2165/11591320-000000000-00000.
7
Neuroprotection in Parkinson's disease: an elusive goal.
Semin Neurol. 2007 Apr;27(2):106-12. doi: 10.1055/s-2007-971168.
8
Therapies to Slow, Stop, or Reverse Parkinson's Disease.
J Parkinsons Dis. 2018;8(s1):S115-S121. doi: 10.3233/JPD-181481.
9
Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
Exp Neurol. 2017 Dec;298(Pt B):137-147. doi: 10.1016/j.expneurol.2017.10.001. Epub 2017 Oct 5.
10
Recent Advances in Drug Repurposing for Parkinson's Disease.
Curr Med Chem. 2019;26(28):5340-5362. doi: 10.2174/0929867325666180719144850.
本文引用的文献
1
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
J Comp Eff Res. 2022 Aug;11(12):889-904. doi: 10.2217/cer-2022-0031. Epub 2022 Jun 27.
2
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
Mov Disord. 2021 Feb;36(2):415-423. doi: 10.1002/mds.28322. Epub 2020 Oct 19.
3
Vitis vinifera: An Alternative for the Prevention of Neurodegenerative Diseases.
J Oleo Sci. 2020 Oct 7;69(10):1147-1161. doi: 10.5650/jos.ess20109. Epub 2020 Sep 10.
4
Ferroptosis and its potential role in the physiopathology of Parkinson's Disease.
Prog Neurobiol. 2021 Jan;196:101890. doi: 10.1016/j.pneurobio.2020.101890. Epub 2020 Jul 26.
5
Dopamine D1 Receptors Regulate Spines in Striatal Direct-Pathway and Indirect-Pathway Neurons.
Mov Disord. 2020 Oct;35(10):1810-1821. doi: 10.1002/mds.28174. Epub 2020 Jul 9.
6
Historical Perspective: Models of Parkinson's Disease.
Int J Mol Sci. 2020 Apr 2;21(7):2464. doi: 10.3390/ijms21072464.
7
Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice.
Gut. 2019 May;68(5):829-843. doi: 10.1136/gutjnl-2018-316844. Epub 2018 Dec 15.
8
Epigallocatechin-3-Gallate Protects and Prevents Paraquat-Induced Oxidative Stress and Neurodegeneration in Knockdown dj-1-β Drosophila melanogaster.
Neurotox Res. 2018 Oct;34(3):401-416. doi: 10.1007/s12640-018-9899-x. Epub 2018 Apr 17.
9
Low dose doxycycline decreases systemic inflammation and improves glycemic control, lipid profiles, and islet morphology and function in db/db mice.
Sci Rep. 2017 Oct 31;7(1):14707. doi: 10.1038/s41598-017-14408-7.
10
Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease.
Neurobiol Aging. 2016 Dec;48:61-71. doi: 10.1016/j.neurobiolaging.2016.08.004. Epub 2016 Aug 16.
Zotero 插件